Umeå University Hospital

In 1992, the ALS Clinical Center was established at Umeå University Hospital. This is now the principal center for diagnosing and caring of patients with neuromuscular diseases in northern Sweden. The clinical team also performs second-opinion evaluations of patients from other parts of Sweden and from abroad. Since 1992 the center has conducted clinical phase 1—3 trials which concern investigator initiated clinical trials as well as studies with the industry. The ALS Clinical Center is part of the larger ALS Research Consortium in Umeå that also performs genetic, histopathology and molecular-pathology studies. The focus is on studying SOD1 and its role as a prion in causing cell death.

Contact
Location
Umeå University, Postadress:, Umeå, Sweden

Specialists

Peter Andersen

Professor of Neurology and Senior Neurologist

Professor Andersen obtained his medical degree from Copenhagen University and specialised in […]

Peter Andersen
Current trials
Recruiting
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Recruiting
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
In preparation
Phase iii

The Lighthouse 2 trial

Investigator initiated trial
The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.
Read more
In preparation
Phase iii

MAGNET

Platform trial
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more